Gossamer Bio is trading 5.8% down now at $11.01, and the cause remains unclear.

  • No clear company-specific announcement or catalyst dated September 23, 2026 was identified in available coverage.
  • Recent reporting instead focuses on the September 10 1-for-80 reverse stock split and related Nasdaq compliance efforts, which predate the current decline. Broader equities are weaker, but biotechnology is stronger.